Theravance Inc (THRX.OQ)

THRX.OQ on NASDAQ Stock Exchange Global Select Market

23 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for THRX.OQ


Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including... (more)


Beta: 1.86
Market Cap (Mil.): $1,974.79
Shares Outstanding (Mil.): 115.01
Dividend: 0.25
Yield (%): 5.82


  THRX.OQ Industry Sector
P/E (TTM): -- 32.88 33.65
EPS (TTM): -1.23 -- --
ROI: -23.97 18.21 17.48
ROE: -- 18.89 18.31
Search Stocks

BRIEF-GSK and Theravance says gains approval in Japan for Anoro Ellipta

* Press_release:anoro ellipta(umeclidinium/vilant erol) gains approval in Japan for the treatment of COPD

04 Jul 2014

BRIEF-GSK, Theravance submit sNDA to U.S. FDA for Breo Ellipta

* GSK and Theravance announce submission to US regulatory authorities for Fluticasone Furoate/Vilanterol in asthma

30 Jun 2014


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks